tradingkey.logo

PharmaCyte Biotech Inc

PMCB
0.765USD
-0.005-0.68%
收盤 12/24, 13:00美東報價延遲15分鐘
5.20M總市值
虧損本益比TTM

PharmaCyte Biotech Inc

0.765
-0.005-0.68%

關於 PharmaCyte Biotech Inc 公司

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

PharmaCyte Biotech Inc簡介

公司代碼PMCB
公司名稱PharmaCyte Biotech Inc
上市日期Sep 11, 2003
CEOSilverman (Joshua N)
員工數量2
證券類型Ordinary Share
年結日Sep 11
公司地址3960 Howard Hughes Parkway, Suite 500
城市LAS VEGAS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編89169
電話19175952850
網址https://pharmacyte.com/
公司代碼PMCB
上市日期Sep 11, 2003
CEOSilverman (Joshua N)

PharmaCyte Biotech Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月14日 週日
更新時間: 12月14日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Intracoastal Capital, L.L.C.
5.20%
Schechter (Jonathan L)
1.31%
Geode Capital Management, L.L.C.
1.25%
Equitec Proprietary Markets, LLC
0.82%
Asher (Daniel B)
0.82%
其他
90.61%
持股股東
持股股東
佔比
Intracoastal Capital, L.L.C.
5.20%
Schechter (Jonathan L)
1.31%
Geode Capital Management, L.L.C.
1.25%
Equitec Proprietary Markets, LLC
0.82%
Asher (Daniel B)
0.82%
其他
90.61%
股東類型
持股股東
佔比
Corporation
5.20%
Individual Investor
3.56%
Investment Advisor
1.58%
Investment Advisor/Hedge Fund
1.44%
Hedge Fund
1.25%
Research Firm
0.02%
其他
86.96%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
61
457.38K
6.73%
-604.80K
2025Q2
66
1.28M
18.72%
-522.91K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Intracoastal Capital, L.L.C.
527.38K
1.12%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.11%
--
--
Sep 15, 2025
Geode Capital Management, L.L.C.
126.60K
0.27%
-12.33K
-8.88%
Jun 30, 2025
Equitec Proprietary Markets, LLC
82.73K
0.18%
--
--
Jun 30, 2025
Asher (Daniel B)
82.73K
0.18%
--
--
Dec 31, 2024
Renaissance Technologies LLC
49.80K
0.11%
+300.00
+0.61%
Jun 30, 2025
The Vanguard Group, Inc.
194.45K
0.41%
-71.00
-0.04%
Jun 30, 2025
Silverman (Joshua N.)
50.00K
0.11%
--
--
Sep 15, 2025
Schonfeld Strategic Advisors LLC
26.20K
0.06%
+700.00
+2.75%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

PharmaCyte Biotech Inc的前五大股東是誰?

PharmaCyte Biotech Inc的前五大股東如下:
Intracoastal Capital, L.L.C.
持有股份:527.38K
佔總股份比例:1.12%。
Schechter (Jonathan L)
持有股份:50.00K
佔總股份比例:0.11%。
Geode Capital Management, L.L.C.
持有股份:126.60K
佔總股份比例:0.27%。
Equitec Proprietary Markets, LLC
持有股份:82.73K
佔總股份比例:0.18%。
Asher (Daniel B)
持有股份:82.73K
佔總股份比例:0.18%。

PharmaCyte Biotech Inc的前三大股東類型是什麼?

PharmaCyte Biotech Inc 的前三大股東類型分別是:
Intracoastal Capital, L.L.C.
Schechter (Jonathan L)
Geode Capital Management, L.L.C.

有多少機構持有PharmaCyte Biotech Inc(PMCB)的股份?

截至2025Q3,共有61家機構持有PharmaCyte Biotech Inc的股份,合計持有的股份價值約為457.38K,占公司總股份的6.73% 。與2025Q2相比,機構持股有所增加,增幅為-11.99%。

哪個業務部門對PharmaCyte Biotech Inc的收入貢獻最大?

在--,--業務部門對PharmaCyte Biotech Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI